{"id":"lysine-acetylsalicylate","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal bleeding or ulceration"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Increased bleeding risk"}]},"_chembl":{"chemblId":"CHEMBL1697753","moleculeType":"Small molecule","molecularWeight":"326.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As an acetylsalicylate derivative, this drug irreversibly inhibits COX-1 and COX-2 enzymes, reducing production of prostaglandins and thromboxane A2. The lysine salt formulation enhances solubility and absorption compared to standard aspirin, allowing for faster onset of action while maintaining the same mechanism of action for pain relief, inflammation reduction, and antiplatelet activity.","oneSentence":"Lysine acetylsalicylate is a salt form of aspirin that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic, anti-inflammatory, and antiplatelet effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:40.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute pain and fever"},{"name":"Cardiovascular protection and antiplatelet therapy"},{"name":"Inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT02813824","phase":"PHASE3","title":"Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-11-14","conditions":"Lynch Syndrome","enrollment":852},{"nctId":"NCT06565728","phase":"PHASE1","title":"Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-11-03","conditions":"Fetal Growth Retardation","enrollment":99},{"nctId":"NCT02817789","phase":"PHASE3","title":"Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-05-09","conditions":"Aortic Valve Stenosis","enrollment":50},{"nctId":"NCT02833948","phase":"PHASE3","title":"Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2016-05","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases","enrollment":231},{"nctId":"NCT02285153","phase":"PHASE3","title":"Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2011-11-15","conditions":"Critical Illness","enrollment":15},{"nctId":"NCT03370705","phase":"PHASE3","title":"Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone","status":"UNKNOWN","sponsor":"Alfa Wassermann Tunisia","startDate":"2019-01-31","conditions":"Peripheral Arterial Obstructive Disease","enrollment":156},{"nctId":"NCT02439996","phase":"PHASE3","title":"Different Doses of IVIG for Kawasaki Disease","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2014-01","conditions":"Kawasaki Disease","enrollment":404},{"nctId":"NCT01011257","phase":"PHASE4","title":"Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.","status":"WITHDRAWN","sponsor":"Neil Kleiman, MD","startDate":"2009-09","conditions":"Coronary Artery Disease","enrollment":""},{"nctId":"NCT02330640","phase":"PHASE4","title":"A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2016-01","conditions":"Antiplatelet Therapy of Coronary Artery Bypass","enrollment":137},{"nctId":"NCT01633528","phase":"PHASE3","title":"The Effect of Low Dose Aspirin in Increasing the Chance of Pregnancy","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2012-05","conditions":"Infertility","enrollment":60},{"nctId":"NCT02929888","phase":"PHASE2, PHASE3","title":"Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate in STEMI Patients","status":"UNKNOWN","sponsor":"Fundacion Investigacion Interhospitalaria Cardiovascular","startDate":"2016-10","conditions":"Acute Myocardial Infarction","enrollment":60},{"nctId":"NCT01572961","phase":"NA","title":"Microvascular Function Assessment in Healthy Subjects","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2010-11","conditions":"Physiology of Microvascular Skin","enrollment":16},{"nctId":"NCT00986765","phase":"PHASE3","title":"Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-06","conditions":"Preeclampsia","enrollment":257},{"nctId":"NCT02612480","phase":"NA","title":"Ticagrelor in Human Endotoxemia Response to Human Endotoxemia","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-10","conditions":"Endotoxemia","enrollment":40},{"nctId":"NCT00910065","phase":"PHASE3","title":"BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-03","conditions":"Acute Coronary Syndrome","enrollment":270},{"nctId":"NCT02243137","phase":"PHASE1","title":"Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate","status":"COMPLETED","sponsor":"David Vivas","startDate":"2013-05","conditions":"Adverse Effect of Antithrombotic Drugs","enrollment":30},{"nctId":"NCT01379079","phase":"PHASE4","title":"Aspirin in Reduction of Tension II Study","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2011-04","conditions":"Hypertension, Cardiovascular Diseases","enrollment":290},{"nctId":"NCT01935193","phase":"PHASE4","title":"Aspirin Resistance Reversibility in Diabetic Patients","status":"UNKNOWN","sponsor":"Azienda Ospedaliera San Giovanni Battista","startDate":"2011-11","conditions":"Aspirin Resistance","enrollment":160},{"nctId":"NCT01094483","phase":"PHASE1","title":"A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-03","conditions":"Platelet Inhibition","enrollment":40},{"nctId":"NCT00815126","phase":"NA","title":"Nasal Provocation Test With Lysine-Acetylsalicylate (ASA) in Patients With Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Hypersensitivity","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2008-11","conditions":"Aspirin Hypersensitivity, NSAIDs Hypersensitivity","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":274,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Flectadol","Cardirene","Inyesprin"],"phase":"marketed","status":"active","brandName":"lysine acetylsalicylate","genericName":"lysine acetylsalicylate","companyName":"Azienda Ospedaliera San Giovanni Battista","companyId":"azienda-ospedaliera-san-giovanni-battista","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lysine acetylsalicylate is a salt form of aspirin that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic, anti-inflammatory, and antiplatelet effects. Used for Acute pain and fever, Cardiovascular protection and antiplatelet therapy, Inflammatory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}